ProMIS Neurosciences (NASDAQ:PMN) versus Rigel Pharmaceuticals (NASDAQ:RIGL) Head-To-Head Analysis

ProMIS Neurosciences (NASDAQ:PMN) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

Volatility & Risk

ProMIS Neurosciences has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, Rigel Pharmaceuticals has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500.

Valuation & Earnings

This table compares ProMIS Neurosciences and Rigel Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProMIS Neurosciences	$10,000.00	2,427.01	-$13.21 million	($0.74)	-1.73
Rigel Pharmaceuticals	$116.88 million	2.47	-$25.09 million	($1.20)	-13.68

ProMIS Neurosciences has higher earnings, but lower revenue than Rigel Pharmaceuticals. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than ProMIS Neurosciences, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

50.1% of ProMIS Neurosciences shares are owned by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 6.4% of ProMIS Neurosciences shares are owned by company insiders. Comparatively, 9.0% of Rigel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares ProMIS Neurosciences and Rigel Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProMIS Neurosciences	N/A	-587.38%	-133.87%
Rigel Pharmaceuticals	-10.92%	N/A	-11.68%

Analyst Ratings

This is a breakdown of current ratings and target prices for ProMIS Neurosciences and Rigel Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProMIS Neurosciences	0	0	1	0	3.00
Rigel Pharmaceuticals	0	2	2	0	2.50

ProMIS Neurosciences currently has a consensus price target of $8.00, suggesting a potential upside of 525.00%. Rigel Pharmaceuticals has a consensus price target of $31.13, suggesting a potential upside of 89.56%. Given ProMIS Neurosciences’ stronger consensus rating and higher possible upside, equities analysts clearly believe ProMIS Neurosciences is more favorable than Rigel Pharmaceuticals.

About ProMIS Neurosciences

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

About Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.